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The diffuse large B-cell non-Hodgkin lymphomas (NHL) encom-
pass a heterogeneous group of NHL with respect to the morpho-
logical spectrum and clinical behaviour. In the Kiel classification,
diffuse large B-cell NHL are subclassified on the basis of their
morphology in three main categories of diffuse centroblastic
lymphoma (including the monomorphic, polymorphic, centro-
cytoid and multilobated subtypes), B-immunoblastic lymphoma
and anaplastic large cell lymphoma (Lennert and Feller, 1990).
Patients with an immunoblastic NHL were always considered to
have a significantly worse prognosis (Rosenberg et al, 1982; Stein
and Dallenbach, 1992). On the basis of the analysis of the original
series of the Working Formulation (WF), immunoblastic NHL was
set apart from the other large B-cell NHL and considered to be
of high-grade malignancy (Rosenberg et al, 1982; Stein and
Dallenbach, 1992; van Heerde et al, 1996). These views have been
challenged, however, by other investigators. In the proposed
Revised European–American Classification of Lymphoid
Neoplasms (REAL classification), the diffuse large B-cell
lymphomas are grouped together, because of a presumed lack of
reproducibility of histologic subclassification in daily practice
and, therefore, subtyping of the diffuse large B-cell NHL is
considered to be of minor clinical significance (Harris et al, 1994;
Berard and Hutchison, 1997).
Preliminary presentations of the new WHO classification show
that the view of the REAL classification is largely adopted (Jaffe
et al, 1997). Specific morphological variants have been defined
with the purpose of recognizing diagnostic pitfalls, including,
for example, anaplastic, T-cell/histiocyte rich, centroblastic and
immunoblastic NHL. A clinical significance of these subtypes is,
however, not implicated. Only primary mediastinal (thymic) large
B-cell NHL and intravascular large B-cell NHL are listed as sepa-
rate clinico-pathological entities on the basis of their specific
presentation and clinical course (Jaffe et al, 1997).
In this retrospective study, we analysed whether subclassifica-
tion of large B-cell NHL, concentrating on the original Kiel classi-
fication criteria of B-immunoblastic, centroblastic polymorphic
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of large B-cell NHL as a guideline in therapy choice.
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Correspondence to: Mrs Dr JW Baarssubtype and centroblastic (including monomorphic, centrocytoid
and multilobated subtypes) NHL, is of clinical significance with
regard to parameters at presentation, including specific localiza-
tions, response to therapy, patterns of relapse as well as clinical
outcome (overall and disease-free survival), in order to investigate
whether it may be justifiable to draw therapeutic consequences
from the histological subclassification of large B-cell NHL.
PATIENTS AND METHODS
Patients
For this retrospective study, all patients diagnosed as having an
immunoblastic B-cell NHL were retrieved from the files of the
Lymphoma Review Panel of the Comprehensive Cancer Center
Amsterdam (CCCA) (n = 45). Patients treated according to the
guidelines of the CCCA between 1984 and 1994 were analysed
for this study. Patients diagnosed as having a centroblastic NHL
(monomorphic, centrocytoid and multilobated subtypes, further
called centroblastic NHL) and centroblastic polymorphic subtype
NHL by the CCCA Lymphoma Review Panel and who were
treated in the same period according to the CCCA guidelines in the
Netherlands Cancer Institute were used as reference groups
(n = 198). The patients included into this study were all previously
untreated. The patients with a centroblastic or centroblastic poly-
morphic NHL were all treated in the Netherlands Cancer Institute.
From the 45 patients with an immunoblastic NHL, 30 patients
were treated in the Netherlands Cancer Institute and 15 patients in
5 other hospitals connected to the Comprehensive Cancer Center
Amsterdam. As stated above, the treatment guidelines were similar
for all institutes.
Clinical records were reviewed (JWB, EMW) and the following
parameters at presentation were recorded: age, stage, performance
status, sex, LDH, number and localization of extranodal sites,
bulky disease (defined as a mass ³ 5 cm) and the presence of B-
symptoms. The therapeutic regimen was recorded, including infor-
mation on the composition of the chemotherapeutic schedules,
dose reduction of the chemotherapy and radiotherapy data.
Response to therapy, time to relapse, second-line therapy for
relapses, time and cause of death, date last seen and disease status
at the time of review (alive with or without disease) were included.
Patients were excluded from this study on the following criteria:
a recognized disease phase of a follicular centrocytic/centroblastic
NHL or another type of low-grade B-cell NHL, with subsequent
transformation to a large B-cell NHL, human immunodeficiency
virus (HIV) related NHL, secondary NHL after previous treatment
of an unrelated malignancy and proven T-cell phenotype upon
review. Patients of whom no histological slides were available for
review and patients with inadequate histological or incomplete
clinical data (two or more prognostic parameters lacking) were
also excluded from this study.
Histology
All cases were originally diagnosed and classified according to
the Kiel-classification and Working Formulation by the CCCA
Lymphoma Review Panel, consisting of at least three experienced
haematopathologists. In all cases, a minimum panel of immunohis-
tochemical markers was available, including CD20 (L26), MB2,
CD45RO (UCHL 1), CD43 (MT1) and CD45RA (LCA) and in
later years also including CD3, CD30 and CD79a (JCB 117).
From 229 cases (45 patients with immunoblastic NHL and 184
patients with centroblastic or centroblastic polymorphic subtype
NHL), histological slides were still available for review, and these
cases were reclassified according to the updated Kiel classification
by two haematopathologists, independently from each other (DdJ,
PvH). In case of discrepancy between the reviewers or with the
original CCCA panel diagnosis, cases were reviewed together
to come to a consensus diagnosis. Immunohistochemical studies
were completed, if necessary. According to the criteria defined
by the updated Kiel classification (Lennert and Feller, 1990)
(and adopted by the recent WHO classification proposal),
immunoblastic B-NHL was defined by a tumour cell population of
³ 90% immunoblasts, centroblastic NHL as ≤ 10% immunoblasts
and centroblastic polymorphic subtype NHL as between 10–90%
immunoblasts. A further subdivision was recorded as group 1 =
10–25% immunoblasts, group 2 = 25–50% immunoblasts, group
3 = 50–75% immunoblasts and group 4 = 75–90% immunoblasts
of the total malignant B-cell infiltrate. In order to investigate the
additional value of the immunohistochemical identification of
immunoblasts in quantifying their number, an immunohisto
chemical analysis was performed with the plasma cell-related
antibodies CD138 (Syndecan-1, 1D4/B-B4 antibody, Serotec Ltd,
Oxford, UK) (Wijdenes et al, 1996) and VS38c (Dako A/S,
Glostrup, Denmark) on 19 cases of immunoblastic NHL, 21 cases
of centroblastic NHL and 21 cases of polymorphic centroblastic
NHL. Subclassification on the basis of this additional immuno-
histochemical information was performed without knowledge of
the previous diagnosis.
Statistical analysis
Overall survival and disease-free survival curves were estimated
using the Kaplan–Meier method. The univariate associations
between different clinical and histological features with overall
and disease-free survival were tested with the log-rank test.
Stratified log-rank tests were performed to study the prognostic
value of histological subclassification, adjusting for the interna-
tional prognostic index (Shipp et al, 1993). In addition to the
stratified log-rank tests, the Cox proportional hazards model was
used. A step forward procedure was performed to study the risk
associated with different histological subtypes, adjusting for the
international prognostic index (Shipp et al, 1993), sex, B-symp-
toms, bulky disease (³ 5 cm) and bone marrow involvement.
Association of different clinical features with histological cell
type was studied using the Pearson chi-square test. All reported
P-values were obtained from two-sided tests. P-values of > 0.05
are reported as not significant.
RESULTS
Histology
Forty-five cases with immunoblastic NHL and 198 cases with
centroblastic or centroblastic polymorphic subtype were retrieved
from the files of the Lymphoma Review Panel of the CCCA
between 1984 and 1994.
After exclusion according to the above-mentioned criteria,
177 patients with large B-cell NHL were included in this study.
Thirty-six (20.3%) of the patients were diagnosed to have an
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immunoblastic B-cell NHL (IB NHL). Of the 45 originally
retrieved cases of immunoblastic NHL, 2 cases were excluded
bacause of lack of enough clinical data, 3 cases were excluded on
the basis of not-proven B-cell phenotype (most probably T-NHL),
3 cases were reclassified as centroblastic polymorphic subtype
NHL upon review (group 4, between 75 and 90% immunoblasts)
and 1 patient was recognized as having a follicular centrocytic/
centroblastic NHL transformed to an immunoblastic B-cell NHL at
the time of the first presentation.
Of the 198 originally retrieved cases of centroblastic NHL or
centroblastic polymorphic subtype NHL, 57 cases were excluded for
the following reasons: no histological slides available for review (14
cases), inadequate histology (3 cases), incomplete clinical data (27
cases), HIV-related NHL (9 cases), follicular centroblastic/centro-
cytic NHL transformed to a centroblastic NHL and centroblastic
polymorphic subtype respectively at the time of presentation (2
cases) and development of a large B-cell NHL after previous treat-
ment for Hodgkin’s disease (2 cases). Of the 141 included cases, 69
(39%) of the cases were classified as centroblastic polymorphic
subtype NHL (CB-Poly NHL) and 72 (40.3%) as centroblastic NHL
(CB NHL). In 8/141 (5.7%) cases, review resulted in divergence of
classification between the centroblastic and centroblastic polymor-
phic subtype (2 patients originally diagnosed to have a CB NHL had
a CB-Poly NHL upon review, 6 patients originally diagnosed to
have a CB-Poly NHL had a CB NHL upon review). No cases with
a centroblastic or centroblastic polymorphic subtype NHL were
reclassified as immunoblastic NHL. Thus, in the total group of 177
patients, divergence in histological subclassification between the
two haematopathologists occurred in 11 patients (6.2%). The intra-
observer variability for the two haematopathologists (all slides were
reviewed twice with an interval of at least 2 months) were 6% (n =
10) and 10% (n = 18) respectively. In case of discrepancy between
the first and second observation and in case of discrepancy between
the two observers, a consensus diagnosis was made between the two
haematopathologists.
Immunohistochemical staining with CD138 (Syndecan-1,
1D4/B-B4) and VS38c in 61 cases of large B-cell NHL showed
strong staining of reactive plasma cells in all cases. Both markers
were quite sensitive to decline of staining intensity upon long-term
storage of archival unstained paraffin sections. With optimal tissue
quality, reliable and reproducible staining of immunoblasts could
be achieved with a lower intensity than the concomitant reactive
plasma cells (Figure 1). Overall, immunohistochemical identifica-
tion of immunoblasts with CD138 and VS38c was insufficiently
reliable to add significantly to the quantification of immunoblasts
and is probably not useful for the subclassification of large B-cell
NHL.
Clinical parameters at presentation
The clinical characteristics at presentation are summarized in
Table 1.
Patients with an immunoblastic NHL tended to be older than
patients with polymorphic centroblastic or centroblastic NHL. The
patients with an immunoblastic NHL presented more frequently
with stage I or II and one extranodal site than patients with a poly-
morphic centroblastic or centroblastic NHL. No major differences
were found between the subentities of the diffuse large B-cell NHL
with regard to the other prognostic criteria according to the
International Prognostic Index (IPI) according to Shipp et al
(1993: performance status, serum concentrations of LDH, number
of extranodal sites [≤ 1 versus > 1], stage). In addition, the
distribution of prognostic groups according to the IPI (Shipp et al,
1993) was similar for the three histologic subentities (Table 1).
The patients with polymorphic centroblastic NHL tended to
present more often with bone marrow involvement than patients
with immunoblastic or centroblastic NHL (Table 1).
The extranodal NHL localizations at presentation are summa-
rized in Table 2. It should be noted that none of the subtypes of
large B-cell NHL showed preference for localization in a partic-
ular site, except localization of centroblastic NHL in the thyroid.
The numbers are, however, too small to draw definite conclusions.
There were no differences in localization and frequency of
extranodal relapses.
Therapy
The majority of the patients (52%, 92/177) were treated with
CHOP-(like) regimens and radiotherapy. Thirty-four patients
(19.2%) received only CHOP-like regimens, 47 patients (26.6%)
were treated only with radiotherapy (the majority of the patients
treated only with radiotherapy had stage I or II and were treated
before 1990). According to the CCCA guidelines, 11 of these 47
patients should have received chemotherapy because of stage
and/or bulky disease. (Anthracycline containing) chemotherapy
was omitted for the following reasons: erroneous initial diagnosis
of seminoma in a patient with centroblastic polymorphic subtype
NHL, patient’s refusal (1 patient with centroblastic NHL, 1 patient
Figure 1 Immunohistochemical staining with CD138 (Syndecan-1, 1D4/B-
B4) (A) and VS38C (B) in 2 cases of immunoblastic NHL. Immunoblasts
show a lower staining intensity than concomitant plasma cells
A
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with immunoblastic NHL), age over 80 years (2 patients with
immunoblastic NHL, 2 patients with centroblastic polymorphic
subtype NHL, 4 patients with centroblastic NHL).
Four patients did not receive any therapy at all because of rapid
deterioration (2 patients with immunoblastic NHL), very old age
(1 patient with centroblastic polymorphic NHL, 91-year-old
patient) and no evidence of disease after surgical resection (1
patient with centroblastic NHL). The dose reductions and response
to the CHOP-like regimens and radiotherapy are summarized in
Table 3. The response to treatment was similar in the different
histological subgroups.
Dose reductions occurred more frequently in patients with a
centroblastic polymorphic or centroblastic NHL than in patients
with an immunoblastic NHL.
Clinical outcome
The median follow-up for all 177 patients was 5 years and 4
months and was similar in all histological subtypes (5 years and 4
months for the 72 patients with centroblastic NHL, 5 years and 3
months for the 69 patients with centroblastic polymorphic subtype
NHL and 5 years and 8 months for the 36 patients with
immunoblastic NHL).
The clinical outcome (last evaluation in December 1996) is
summarized in Table 4. The major cause of death was NHL in all
three groups.
Multivariate analysis (including sex, B-symptoms, bulky
disease  ³ 5 cm, bone marrow involvement, the international prog-
nostic index) showed only prognostic significance in relation to
overall and disease-free survival for the international prognostic
index (IPI).
In addition to the IPI, histological subclassification had an inde-
pendent prognostic significance. With regard to disease-free
survival, the IPI risk group 2, 3 and 4 together showed a risk ratio
of 2.12 compared with risk group 1 (P = 0.0001). Patients with an
immunoblastic NHL or centroblastic polymorphic NHL showed in
comparison to the patients with a centroblastic NHL a risk ratio of
Table 1 Clinical parameters at presentation of 177 patients with large B-cell
NHL
IB NHLa CB-Poly NHL CB NHL P-value
No. of patients 36 69 72
Sex
M 19 (52.8%) 34 (49.3%) 35 (48.6%)
F 17 (47.2%) 35 (50.7%) 37 (51.4%) 0.916
Age in years
Mean ± s.d.b 66 ± 14.3 60 ± 16 59 ± 16
Median 66 61 59
Range 29–90 17–94 21–83
≤ 60 11 (30.6%) 31 (44.9%) 39 (54.2%)
> 60 25 (69.4%) 38 (55.1%) 33 (45.8%) 0.066
PSc
0–1 27 (75%) 57 (82.6%) 58 (80.6%)
2–4 9 (25%) 8 (11.6%) 11 (15.3%)
Unknown 0 4 (5.8%) 3 (4.1%) 0.255
B-symptoms
present 6 (18.2%) 21 (30.9%) 20 (29%) 0.388
Stage
I–II 29 (82.9%) 39 (56.5%) 46 (63.9%)
III–IV 7 (17.1%) 30 (43.5%) 26 (36.1%) 0.029
Extranodal sites at
presentation 23 (63.9%) 24 (34.8%) 36 (50%) 0.012
> 1 extranodal site 2 (5.6%) 4 (5.8%) 5 (6.9%) 0.945
Bulky disease
³ 5 cm 20 (76.9%) 50 (75.8%) 56 (78.9%) 0.909
LDH
³ 1.5 normal 8 (22.2%) 21 (30.4%) 19 (30.7%)
< 1.5 normal 21 (58.3%) 41 (59.4%) 46 (63.9%) 0.783d
Unknown 7 (19.5%) 7 (10.2%) 7 (5.4%)
Bone marrow
involvement 3 (8.3%) 12 (17.4%) 4 (5.6%) 0.066
IPI risk groupe
Risk group 1 22 (61.1%) 41 (59.4%) 41 (56.9%)
Risk group 2–4 14 (38.9%) 28 (40.6%) 31 (43.1%) 0.908
aIB NHL = immunoblastic NHL; CB-Poly NHL = centroblastic polymorphic
subtype NHL; CB NHL = centroblastic NHL. bs.d. = standard deviation.
cPS = Performance status according to the WHO criteria. dP-value reflects to
the number of patients of whom the LDH was known. eIPI risk groups as
defined by Shipp et al (1993).
Table 2 Place of extranodal sites at initial diagnosis
IB NHLa CB-Poly NHL CB NHL
Total no. of patients 36 69 72
No of patients with extranodal sites 23b 24 36
Nose/throat region including sinus 10 (43.4%)c 8 (33.3%) 12 (33.3%)
Central nervous system 2 (8.7%) 3 (12.5%) 1 (2.7%)
Testis 3 (13%) 2 (8.4%) 1 (2.7%)
Gastro-intestinal 3 (13%) 4 (16.7%) 5 (13.8%)
Cutis/subcutis 3 (13%) 3 (12.5%) 5 (13.8%)
Bones (not bone marrow) 2 (8.6%) 5 (20.8%) 5 (13.8%)
Thyroid gland 0 (0%) 0 (0%) 3 (8%)
Other 3 (13%) 3 (12.5%) 9 (25%)
aIB NHL = immunoblastic NHL;CB-Poly NHL = centroblastic polymorphic
subtype NHL; CB = centroblastic NHL. b1 patient with an IB NHL had 2 and 1
patient had 3 extranodal sites, 4 patients with CB-Poly NHL had 2 extranodal
sites, 5 patients with CB NHL had 2 extranodal sites. cThe percentages
reflect to the total number of patients with extranodal localizations within the
histological subtype of large B-cell NHL.
Table 3 Response to first line treatment
IB NHLa CB-Poly NHL CB NHL
Total no. of patients 36 69 72
CHOP-like therapy 20 (55.6%)b 48 (69.6%) 58 (80.6%)
Dose reductions
< 50% 1 (5%) 15 (31.3%) 22 (37.9%)
³ 50% 2 (10%) 2 (4.2%) 2 (3.4%)
Radiotherapy 21 (58.3%) 56 (81.2%) 62 (86.1%)
Dose reduction RT 1 (4.8%) 4 (7.1%) 4 (6.5%)
CHOP-like therapy
with radiotherapy 7 (19.4%) 35 (50.7%) 50 (69.4%)
CHOP-like therapy only 13 (36.1%) 13 (18.8%) 8 (11.1%)
Radiotherapy only 14 (38.9%) 21 (30.4%) 12 (16.7%)
No therapy 2 (5.6%) 1 (1.5%) 1 (1.4%)
Response to therapy
CRc 27 (75%) 51 (73.9%) 55 (76.4%)
PR 2 (5.6%) 5 (7.2%) 7 (9.7%)
SD 0 0 1 (1.4%)
PD 5 (13.9%) 11 (15.9%) 8 (11.1%)
Not evaluable 2 (5.6%) 2 (2.9%) 1 (1.4%)
aIB NHL = immunoblastic NHL; CB-Poly NHL = centroblastic polymorphic
subtype NHL;CB = centroblastic NHL. bThe percentages reflect to the total
number of the subentities. cCR = complete remission; PR = partial remission;
SD = stable disease; PD = progressive disease according to the WHO
criteria.1774 JW Baars et al
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2.01 (P = 0.0105) and 2.02 (P = 0.0019) respectively.
With regard to overall survival, the IPI risk group 2, 3 and 4
together showed a risk ratio of 2.735 (P = 0.0001) in comparison
with risk group 1; the immunoblastic or centroblastic polymorphic
NHL subtypes showed a risk ratio of 1.819 (P = 0.0391) and 1.712
(P = 0.0248) respectively in comparison with centroblastic NHL.
The overall survival and disease-free survival curves by histo-
logic subtypes are shown in Figure 2. The 5-year disease-free
survival for patients with a centroblastic NHL was 53.4%, for
patients with an immunoblastic or centroblastic polymorphic
subtype NHL 26.9% and 32% (log-rank test stratified by the risk
groups as defined by the IPI: P = 0.004); the 5-year overall
survival was 56.3%, 39.1% and 41.6% respectively (log-rank test,
stratified by the risk groups as defined by the IPI: P = 0.022). The
patients with centroblastic NHL thus had a better disease-free and
overall survival compared with patients with a centroblastic poly-
morphic subtype or immunoblastic NHL, even when adjusting for
the IPI.
This retrospective study confirms the value of the IPI criteria
(Shipp et al, 1993): the 5-year overall survival of patients with 0 or 1
risk factor (risk group 1) was 61.8% vs 26.6% for the patients with 2
or more risk factors (risk groups 2–4; log-rank test, stratified by
histological subtype: P < 0.0001); the 5-year disease-free survival
for the patients with 0 or 1 risk factor (risk group 1) was 51.4% vs
21.4% for the patients with 2 or more risk factors (risk groups 2–4;
log-rank test, stratified by histological subtype: P < 0.0001).
We investigated the significance of the relative percentage of
immunoblasts present in the centroblastic polymorphic subtype.
Owing to the small numbers in the groups, the significance of the
of the percentage of immunoblasts on overall or disease free
survival in these subgroups could not be reliably interpreted.
DISCUSSION
This retrospective study shows that patients with an immuno-
blastic and centroblastic polymorphic subtype NHL have a worse
prognosis than patients with a diffuse centroblastic NHL, indepen-
dent of the clinical prognostic criteria as defined by the IPI (Shipp
et al, 1993). Although the initial response to therapy was the
same for the three histological subtypes, the patients with
immunoblastic and centroblastic polymorphic subtype NHL had a
higher risk of recurrence of their NHL than the patients with
centroblastic NHL, resulting in a significantly worse disease-free
and overall survival. The patients with a centroblastic NHL did
show a better outcome, despite the fact that dose reductions in their
chemotherapy schedule occurred more frequently than in the
patients with an immunoblastic NHL and with a similar frequency
in the patients with a centroblastic polymorphic NHL (Table 3).
Therefore, the dose intensity of treatment cannot explain the
different outcome in the three histological subgroups.
Our findings are consistent with the results of the recent study of
Engelhard et al (1997) and former publications (Rosenberg et al,
1982; Stein and Dallenbach, 1992). Other authors, however,
could not demonstrate a prognostic significance of histological
subtyping in large B-cell NHL (Simon et al, 1988; Kwak et al,
1991; Dumont et al, 1992; Koza et al, 1992). The reason for this
discrepancy is not clear, but may be due to the relatively small
number of patients with immunoblastic NHL and/or a different
setting of criteria in most of these retrospective studies. The
discrepancy of the outcome of these studies can also be explained
by the hypothesis that the immunoblastic, centroblastic poly-
morphic subtype and centroblastic NHL are not separate disease
entities, but may represent the extremes of one biological entity.
As many other studies have done, our study confirms the value
of the IPI (Shipp et al, 1993) for patients with NHL of intermediate
and high-grade malignancy.
In addition to the prognostic significance of histological
subtyping of large B-cell NHL, we analysed whether the different
histological categories are related to specific differences in clinical
presentation. The patients with immunoblastic NHL tended to be
older than the patients with centroblastic or centroblastic poly-
morphic subtype NHL. This has also been reported by Kwak et al
(1991). The patients with an immunoblastic NHL presented more
frequently with stage I or II and with one extranodal site than
patients with a centroblastic or centroblastic polymorphic subtype
of NHL.
None of the subtypes of large B-cell NHL showed preference
for localization in a particular site, except localization of centro-
blastic NHL in the thyroid, but the numbers are too small to draw
definite conclusions. We found also no major differences in the
sites of recurrent disease for the histological subtypes of large B-
cell NHL.
Several studies report a more frequent involvement of central
nervous system and bone marrow in patients with an
immunoblastic NHL (Koza et al, 1992; Rodriquez and Khan,
1995). This finding has been used to justify central nervous system
prophylaxis in the treatment schedules of these patients (Koza
et al, 1992). Our findings, however, give no support for this
approach. These results are in line with other studies (Simon et al,
1988; Murphy et al, 1989; Hvizdala et al, 1991; Kwak et al, 1991;
Dumont et al, 1992; Engelhard et al, 1997; Bos et al, 1998).
Therefore, histological subclassification of large B-cell NHL
should not be used to select patients for central nervous system
prophylaxis.
The reproducibility of the subclassification of the large B cell
NHL is a well-known problem. Although the rate of discrepancy
between the two contributory haematopathologists was within
acceptable limits in this study (6.2% of all cases), additional
immunohistochemical stainings that can contribute to improve-
ment of the reproducibility and discrimination between the several
subgroups of NHL might be helpful. In our study, immunohisto-
chemical staining with CD138 (Syndecan-1) and VS38c, both
Table 4 Clinical outcome
IB NHLa CB-Poly NHL CB NHL
Total no. of patients 36 69 72
Alive 14 (38.9%) 26 (37.7%) 41 (56.9%)
Lost to follow-up 2 (5.6%) 1 (1.4%) 1 (1.4%)
Dead 20 (55.2%) 42 (60.9%) 30 (41.7%)
Cause of death
NHL 13 (65%)b 28 (66.7%) 21 (70%)
Toxicity of therapyc 2 (10%) 3 (7.1%) 1 (3.3%)
Second malignancy 1 (5%) 1 (2.4%) 0
Other 3 (15%) 7 (16.7%) 8 (26.7%)
Unknown 1 (5%) 3 (7.1%) 0
aIB NHL = immunoblastic NHL; CB-Poly NHL = centroblastic polymorphic
subtype NHL; CB = centroblastic NHL. bPercentages reflect to the number of
dead patients per subentity. cToxicity of salvage regimens because of
progressive disease, including autologous bone marrow transplantations. Subclassification of diffuse large B-cell NHL 1775
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staining plasma cells and plasmacytoid blasts, was insufficiently
reliable to add significantly to the quantification of immunoblasts.
This can be partly explained by the fact that this marker was quite
sensitive to decline of staining intensity upon storage of archival
unstained paraffin sections. In acquired immunodeficiency
syndrome related large B-cell NHL CD138 (Syndecan-1) expres-
sion was only found in the immunoblastic subtype, although the
degree of expression varied considerably from 0 to 75% (Carbone
et al, 1998), supporting the view that immunohistochemical
staining with CD138 and similar antibodies alone is of minor addi-
tional value for subclassification of large B-cell NHL.
The results of the study of Engelhard et al (Engelhard et al,
1997) and our study support the prognostic significance of
morphological distinction between immunoblastic, centroblastic
polymorphic and centroblastic NHL. This finding merits further
exploration in larger prospective studies with uniformly staged
patients treated with standardized therapies to judge the value of
histological subclassification of large B-cell NHL as a guideline in
therapy choice. Immunohistochemical and molecular biological
data may prove to be of additional value to distinguish
reproducible subentities of diffuse large B-cell NHL and may























































Figure 2 Overall (A) and disease-free (B) survival of 177 patients with a diffuse large cell B-cell NHL by histological subentity (log-rank test stratified by IPI
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This approach may ultimately help to identify patients who may
require other than standard treatment in order to improve their
prognosis (Canellos, 1997).
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